Covid Treatments Now Available in Delaware
Atracare Health and Cape Pharmacy have partnered to expand care in Southern Delaware and offer a Covid treatment for those who have tested positive for Covid. Watch this short video to learn more about eligibility, and how to get a prescription for the Pfizer antiviral treatment by contacting us and scheduling an appointment with your primary care doctor.
Atracare Health and Cape Pharmacy are offering prescriptions for Covid Treatments to qualified patients
Who’s eligible for Paxlovid, and Molnupiravir? If you’re not feeling well and have tested positive you may be eligible. If you have mild to moderate symptoms you may want to consider these two options.
Overview:
- Both meds below are free
- They require a prescription
- Only certain pharmacies have the meds and Cape Pharmacy is one of them
- Neither of these meds are considered monoclonal antibodies
- Neither of these therapies should be considered substitutes for vaccination
- Supplies are limited but access is increasing slowly
- If you’d like to explore treatment options, you should talk to your doctor. All providers at Atracare Health are well-versed in these therapies and happy to prescribe them for qualified patients.
The medications and requirements:
Oral (pills) treatment options for COVID are now available at local pharmacies. These two drugs are:
Molnupiravir (made by Merck) – for patients 18 years of age and older
- Must have a positive COVID test result
- Must start within 5 days of symptom onset, but the sooner the better
- Recommended for patients with mild-to-moderate disease who are at risk for progression to severe disease, including hospitalization or death
- Dose is 800mg every 12 hours for 5 days
Paxlovid (made by Pfizer) – for patients 12 years of age and older weighing at least 40kg
- Must have a positive COVID test result
- Must start within 5 days of symptom onset, but the sooner the better
- Recommended for patients with mild-to-moderate disease who are at risk for progression to severe disease, including hospitalization or death
- Dose is a combination of two meds, taken twice daily for 5 days. These two meds are nirmatrelvir and ritonavir.
More about Pfizer Paxlovid from the Pfizer press release
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
“PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19
In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 deaths in patients who received placebo
Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (3/389 hospitalized with no deaths), compared to 7.0% of patients who received placebo and were hospitalized or died (27/385 hospitalized with 7 subsequent deaths). The statistical significance of these results was high (p<0.0001). Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 subsequent deaths), with high statistical significance (p<0.0001). In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 (1.6%) deaths in patients who received placebo.”
Read the full Paxlovid press release here >
More about Paxlovid from The NIH
On December 22, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir-boosted nirmatrelvir (Paxlovid) for the treatment of patients with mild to moderate COVID-19 who are within 5 days of symptom onset and at high risk of progression to severe disease.1,2 The dose for patients with normal renal function is nirmatrelvir 300 mg (two 150 mg tablets) plus ritonavir 100 mg (one 100 mg tablet) orally twice daily for 5 days. For more information, see the COVID-19 Treatment Guidelines Panel’s (the Panel) statement on treatment options for nonhospitalized patients with mild to moderate COVID-19.
Merck’s Molnupiravir FDA Press Release December 23, 2021
“Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Molnupiravir is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.
Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth. It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because benefit of treatment has not been observed in people when treatment started after hospitalization due to COVID-19.”
FAQ’s Molnupiravir for Treatment of COVID-19
Contact Atracare Health to schedule an appointment to discuss Covid 19 treatment options with your primary care doctor. Follow us on Facebook and/or Instagram to get updates on treatment options as they become available to our community in Southern Delaware.
0 New comments